文献速递中枢神经肿瘤放疗放疗物理与技术

分次立体定向放疗中脑转移瘤靶体积变化对剂量覆盖的影响

Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery.
PubMed 文献 · Radiother Oncol · 2019-08-17

该研究纳入15例仅接受分次立体定向放疗(fSRSonly)患者(18个病灶)和19例术后fSRS(fSRSpostop)患者(20个病灶),比较计划MRI与治疗中重复MRI所示靶体积变化对剂量覆盖的影响。结果显示fSRSonly患者PTV剂量覆盖最大下降达-34.8%(中位3.2%),fSRSpostop患者变化较小(中位-0.5%,范围-4.5%至1.9%)。治疗前靶体积变化可预测治疗中剂量覆盖下降最大的患者。

要点

  • fSRSonly患者治疗中靶体积变化可致PTV剂量覆盖最大下降-34.8%(中位3.2%)。
  • fSRSpostop患者PTV剂量覆盖变化较小,中位-0.5%(-4.5%至1.9%)。
  • 治疗前MRI所示靶体积变化可预测治疗中剂量覆盖下降最大的患者。

核心结论

  • fSRS期间脑转移瘤靶体积变化可导致靶区剂量覆盖恶化,且治疗前可识别最可能受益于治疗中重复MRI的患者。

研究设计与样本

  • 研究纳入15例仅接受fSRS患者(18个病灶)和19例术后fSRS患者(20个病灶),获取计划MRI(MR0)及治疗中重复MRI(MR1),并利用诊断MRI(MRD)评估治疗前靶体积变化的预测价值。

主要发现

  • fSRSonly患者治疗中靶体积变化致PTV剂量覆盖最大下降-34.8%(中位3.2%)。
  • fSRSpostop患者PTV剂量覆盖变化中位-0.5%(范围-4.5%至1.9%),变化和下降较小。
  • 靶体积变化也影响PTV最小剂量:fSRSonly为-2.7 Gy(-16.5至2.3 Gy),fSRSpostop为-0.4 Gy(-4.2至2.5 Gy)。
  • 治疗前MRD与MR0之间靶体积变化可预测治疗中剂量覆盖下降最大的患者。

关键数值与推荐

  • fSRSonly患者PTV剂量覆盖最大下降-34.8%(中位3.2%),PTV最小剂量变化-2.7 Gy(-16.5至2.3 Gy)。
  • fSRSpostop患者PTV剂量覆盖变化中位-0.5%(-4.5%至1.9%),PTV最小剂量变化-0.4 Gy(-4.2至2.5 Gy)。

临床怎么用

  • 对fSRS患者可考虑治疗中重复MRI以评估靶体积变化对剂量覆盖的影响。
  • 利用治疗前MRI所示靶体积变化可筛选最可能受益于治疗中MRI引导的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the impact of target volume changes in brain metastases during fractionated stereotactic radiosurgery (fSRS) and identify patients that benefit from MRI guidance. MATERIAL AND METHODS: For 15 patients (18 lesions) receiving fSRS only (fSRSonly) and 19 patients (20 lesions) receiving fSRS postoperatively (fSRSpostop), a treatment planning MRI (MR0) and repeated MRI during treatment (MR1) were acquired. The impact of target volume changes on the target coverage was analyzed by evaluating the planned dose distribution (based on MR0) on the planning target volume (PTV) during treatment as defined on MR1. The predictive value of target volume changes before treatment (using the diagnostic MRI (MRD)) was studied to identify patients that experienced the largest changes during treatment. RESULTS: Target volume changes during fSRS did result in large declines of the PTV dose coverage up to -34.8% (median = 3.2%) for fSRSonly patients. For fSRSpostop the variation and declines were smaller (median PTV dose coverage change = -0.5% (-4.5% to 1.9%)). Target volumes changes did also impact the minimum dose in the PTV (fSRSonly; -2.7 Gy (-16.5 to 2.3 Gy), fSRSpostop; -0.4 Gy (-4.2 to 2.5 Gy)). Changes in target volume before treatment (i.e. seen between the MRD and MR0) predicted which patients experienced the largest dose coverage declines during treatment. CONCLUSION: Target volume changes in brain metastases during fSRS can result in worsening of the target dose coverage. Patients benefiting the most from a repeated MRI during treatment could be identified before treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hessen E, Nijkamp J, Damen P, et al. Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery. Radiother Oncol. 2019. PMID: 31431379. doi:10.1016/j.radonc.2019.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。